Our primary goal is to pioneer novel immune based preventive and curative interventions in oncology, as we strongly believe that prevention and cure are better than any palliative treatment. Our research focusses on the application of T-cell induction in prophylactic and curative oncologic treatment settings, targeting tumour specific neo-antigens. Among other activities, this involves the search for neo-antigens in mismatch repair deficient colorectal cancer patients. For that purpose my group leads a KWF granted consortium and a clinical trial sponsored by pharma . In addition my research group explores novel ways to combine ICB treatment with radiotherapy , also in the context of investigator initiated a clinical trials.